home / stock / nvs / nvs articles

NVS Articles, Novartis AG - From 01/09/24

Stock Information
Company Name: Novartis AG
Stock Symbol: NVS
Market: NYSE
Website: novartis.com
Menu
NVS NVS Quote NVS Short NVS News NVS Articles NVS Message Board
Get NVS Alerts

News, Short Squeeze, Breakout and More Instantly...
What's Been Happening With Cytokinetics Stock? | Benzinga

Cytokinetics, Incorporated (NASDAQ: CYTK) shares are trading lower on Tuesday, pulling back from Monday strength. What To Know: Cytokinetics stock ...
Why Is Heart Failure Drug-Focused Cytokinetic Stock Trading Higher Today? | Benzinga

Cytokinetics Inc (NASDAQ: CYTK) shares are trading higher after a report on potential takeover talks with Novartis AG (NYSE: NVS). T...

Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today? | Benzinga

Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an update on its business. The co...

Voyager Therapeutics Stock Tanked After-Hours - Here's Why | Benzinga

Voyager Therapeutics, Inc. (NASDAQ: VYGR) shares are trading lower in Thursday's after-hours session after announcing a proposed public of...
Why Is Gene Therapy Focused Voyager Therapeutics Stock Soaring Today? | Benzinga

Voyager Therapeutics Inc (NASDAQ: VYGR) announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsi...

Why Is Neurology Focused Cingulate Stock Trading Higher Today? | Benzinga

On Tuesday, Cingulate Inc (NASDAQ: CING) received FDA guidance for CTx-1301 (dexmethylphenidate), its lead investigational prod...

Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug | Benzinga

The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidn...
Fusion's Pharma's Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% Upside | Benzinga

RBC Capital Markets initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), saying the radiopharmaceutical industry is a bu...

Lantheus Downgraded Due To Reliance On PNT2002; Analyst Cites Comparable Profile To Novartis' Drug | Benzinga

Monday, Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivot...

FDA Approves Merck's Drug Belzutifan For Type Of Advanced Kidney Cancer In Pretreated Cancer Patients | Benzinga

The FDA approved Merck & Co Inc's (NYSE: MRK) Welireg (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhib...
Previous 10 Next 10